Clinical Trials Logo

Clinical Trial Summary

Introduction Due to improvements in diagnostics and treatments, the 5-year survival for patients with breast cancer is 80-90% after initial diagnosis. During treatments, patients typically have consultations weekly and then gradually reduce to annual visits. During this transition from hospital-based care to health self-management, the breast cancer survivors are encouraged to e.g. exercise because of accumulating evidence for the efficacy of exercise training in cancer survivorship, and in the majority of cases, adhere to endocrine treatments to reduce the risk of breast cancer recurrence. Design and methods The study is a one-arm convergent parallel mixed-methods feasibility intervention study. The quantitative data will be the use of the [email protected] app (intervention) and questionnaires (n=50) and the Qualitative data will be semi-structured interviews (n= 15 - 20)

Clinical Trial Description

AIM The aim is to investigate the feasibility and user satisfaction of an app [email protected] version 3.0 and if the app [email protected] can enhance self-efficacy and investigate user statistics and traffic in the app [email protected] by using a convergent parallel Mixed-Methods design. Recruitment and procedure For the quantitative data, the recruitment will follow a consecutive sampling strategy, the follow-up group with the electronic patient-reported outcome (ePRO) and systematic consultations (n= 50) will be recruited from the Endocrinology Out-Clinic at Rigshospitalet, Denmark. For the qualitative data, the participants will be recruited from the group participating in the quantitative data following a nested sampling. The patients will be recruited by the principal investigator Trine Lund-Jacobsen (TLJ), or clinical physicians from the Department of Endocrinology, Rigshospitalet, Denmark. The identification of patients will be given to the principal investigator (TLJ) in case the patients are accepted to be contacted for further written and oral information about the project, letter for the subject's rights is handed out and then be provided for obtaining written consent from the patient. The patients who regret or refuse to give consent to participate in the study will be registered and we will note the reason why the patients refuse or regret participating in the study. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05367830
Study type Interventional
Source Rigshospitalet, Denmark
Contact Trine Lund-Jacobsen
Phone +45 25318056
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date April 30, 2022
Completion date October 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT03080623 - Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
Completed NCT04408560 - Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer N/A
Completed NCT03004534 - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Early Phase 1
Recruiting NCT05020574 - Microbiome and Association With Implant Infections Phase 2
Completed NCT03270111 - High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women N/A
Completed NCT03555227 - USG PECS vs LIA for Breast Cancer Surgery N/A
Recruiting NCT03917082 - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Phase 2
Recruiting NCT04554056 - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF Phase 2/Phase 3
Enrolling by invitation NCT05032404 - Blue Note Therapeutics Product BNT 103 Usability and User Engagement N/A
Active, not recruiting NCT03127995 - Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence N/A
Active, not recruiting NCT02237469 - Prone Breast Radiotherapy Treatment Planning Observational Study N/A
Completed NCT01204125 - Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Phase 2
Recruiting NCT04565054 - Adj. Dyn. Marker-adjusted Personalized Therapy Comparing Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC Phase 3
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Completed NCT03470935 - Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger
Completed NCT03300206 - A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System
Terminated NCT03131011 - Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos N/A
Not yet recruiting NCT05370300 - SNAPS Breast Cancer Patient Study Breast Cancer Patients
Not yet recruiting NCT04606550 - MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study N/A
Recruiting NCT03297346 - Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer N/A